Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 7,746 matching trials from the live ClinicalTrials.gov search.
Conditions
Relapsed Multiple Myeloma, End-stage Renal Disease
Interventions
Carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Detroit, Michigan • Lake Success, New York • Canton, Ohio + 2 more
Conditions
Multiple Myeloma
Interventions
Alnuctamab, Mezigdomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • New Haven, Connecticut • New York, New York
Conditions
DLBCL, Lymphoma, B-Cell
Interventions
Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
75 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Mantle Cell Lymphoma, B Cell Lymphoma
Interventions
Palbociclib, Ibrutinib
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
9
States / cities
Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 6 more
Conditions
Anemia, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, busulfan, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Francisco, California
Conditions
Plasma Cell Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Myeloma, Plasma-Cell, Myeloma-Multiple
Interventions
Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelofibrosis, CMML, Multiple Myeloma
Interventions
Fludarabine, Melphalan, Cyclophosphamide, peripheral blood stem cell transplant
Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Multiple Myeloma
Interventions
Selinexor, Melphalan, Dexamethasone, Autologous Hematopoietic Cell Transplantation (HCT), Fosaprepitant
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Isatuximab, Pomalidomide
Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Imaging Apoptosis for Lymphoma Treatment Response

NCT05048732
Conditions
Diffuse Large B Cell Lymphoma
Interventions
18F-FluorApoTrace
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
Interventions
IPI-145, Rituximab, Bendamustine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Denver, Colorado • Sarasota, Florida • Oklahoma City, Oklahoma + 1 more
Conditions
Chronic Lymphocytic Leukemia (CLL)
Interventions
TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine, 20 mg/kg TRU-016 and bendamustine
Drug
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Denver, Colorado • Augusta, Georgia • Chicago, Illinois + 6 more
Conditions
Mantle Cell Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
Interventions
Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, oral sodium phenylbutyrate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Multiple Myeloma
Interventions
Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more
Conditions
Lymphoma, T Cell, Peripheral, T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma
Interventions
azacitidine, abatacept
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma
Interventions
brexucabtagene autoleucel, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • Stanford, California + 17 more
Conditions
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
alemtuzumab, ofatumumab, biopsy
Biological · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Acute Lymphoblastic Leukemia
Interventions
Gross Motor Function, Knee extension strength, Hand grip strength, Flexibility, Ankle range of motion, Aerobic capacity, Body composition and vital signs
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 10 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Portland, Oregon • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Conditions
Primary Liver Cancer, SCLC, Lymphoma, Melanoma, Multiple Myeloma, Renal Cell Carcinoma, NSCLC
Interventions
MRX34
Drug
Lead sponsor
Mirna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Scottsdale, Arizona • Dallas, Texas • Houston, Texas + 1 more
Conditions
Lymphoma, Multiple Myeloma
Interventions
GPT-QPL
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 1Phase 2 Interventional Results available

LAM Pilot Study With Imatinib Mesylate

NCT03131999
Conditions
Lymphangioleiomyomatosis
Interventions
Imatinib Mesylate 400Mg Capsule, Placebo - Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Charleston, South Carolina